Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches

T Gu, M Zhu, H Huang, Y Hu - Journal of Zhejiang University-SCIENCE B, 2022 - Springer
Chimeric antigen receptor-T (CAR-T) cell therapy, as a novel cellular immunotherapy, has
dramatically reshaped the landscape of cancer treatment, especially in hematological …

[HTML][HTML] Preclinical Anticipation of On-and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review

PJ Dziubańska-Kusibab, E Nevedomskaya… - International Journal of …, 2024 - mdpi.com
The advent of targeted therapies has led to tremendous improvements in treatment options
and their outcomes in the field of oncology. Yet, many cancers outsmart precision drugs by …

[HTML][HTML] Integrated drug profiling and CRISPR screening identify BCR:: ABL1-independent vulnerabilities in chronic myeloid leukemia

SA Awad, O Dufva, J Klievink, E Karjalainen… - Cell Reports …, 2024 - cell.com
Summary BCR:: ABL1-independent pathways contribute to primary resistance to tyrosine
kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) and play a role in …

[HTML][HTML] Molecular aspects of hematological malignancies and benign hematological disorders

AM Găman - International journal of molecular sciences, 2023 - mdpi.com
Hematology represents a dynamic specialty in clinical medicine that requires solid
knowledge of normal and pathological hematopoiesis, cytomorphology, pathology …

[PDF][PDF] GENETIC DETERMINANTS OF DRUG RESPONSE IN DIFFUSE LARGE B-CELL LYMPHOMA

II Issa - 2024 - vbn.aau.dk
The work presented in this PhD thesis was conducted between 2020-2024 during my time
as a PhD student and research assistant at the Department of Hematology, Aalborg …